Ovid Therapeutics Inc.
OVID
$2.42
$0.062.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 718.00K | 132.00K | 6.27M | 130.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 718.00K | 132.00K | 6.27M | 130.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 718.00K | 132.00K | 6.27M | 130.00K |
| SG&A Expenses | 6.67M | 6.42M | 6.79M | 4.88M | 5.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.85M | 13.01M | 12.66M | 11.35M | 12.08M |
| Operating Income | -17.85M | -12.29M | -12.52M | -5.07M | -11.95M |
| Income Before Tax | -16.99M | 9.66M | -12.16M | -4.68M | -10.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.99M | 9.66M | -12.16M | -4.68M | -10.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.99M | 9.66M | -12.16M | -4.68M | -10.24M |
| EBIT | -17.85M | -12.29M | -12.52M | -5.07M | -11.95M |
| EBITDA | -17.81M | -12.28M | -12.51M | -4.97M | -11.81M |
| EPS Basic | -0.12 | 0.12 | -0.17 | -0.06 | -0.14 |
| Normalized Basic EPS | -0.08 | -0.09 | -0.11 | -0.04 | -0.10 |
| EPS Diluted | -0.12 | 0.12 | -0.17 | -0.06 | -0.14 |
| Normalized Diluted EPS | -0.08 | -0.09 | -0.11 | -0.04 | -0.10 |
| Average Basic Shares Outstanding | 136.17M | 81.67M | 71.11M | 71.11M | 71.05M |
| Average Diluted Shares Outstanding | 136.17M | 81.67M | 71.11M | 71.11M | 71.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |